<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E37FE412-1FAE-4F9A-A21C-6ACA5172D4E9"><gtr:id>E37FE412-1FAE-4F9A-A21C-6ACA5172D4E9</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Caswell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FE18353D-5873-46C8-A990-B94F4FA3848A"><gtr:id>FE18353D-5873-46C8-A990-B94F4FA3848A</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Man</gtr:surname><gtr:orcidId>0000-0001-9103-1686</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9E6905FC-C8E1-4853-9800-F2805E536856"><gtr:id>9E6905FC-C8E1-4853-9800-F2805E536856</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Gelder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C7C0FC1F-2464-4404-9921-CAFD2EB08C64"><gtr:id>C7C0FC1F-2464-4404-9921-CAFD2EB08C64</gtr:id><gtr:firstName>Eddie</gtr:firstName><gtr:otherNames>Chung</gtr:otherNames><gtr:surname>Wang</gtr:surname><gtr:orcidId>0000-0002-2243-4964</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D05D7386-7173-4E4C-94C6-B52EDAA849C2"><gtr:id>D05D7386-7173-4E4C-94C6-B52EDAA849C2</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Wilkinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA4A162C-851B-4CEB-BB61-5CB1038C2C8B"><gtr:id>DA4A162C-851B-4CEB-BB61-5CB1038C2C8B</gtr:id><gtr:firstName>Leszek</gtr:firstName><gtr:surname>Borysiewicz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/440DF539-45E2-492D-968F-DA8B55D36568"><gtr:id>440DF539-45E2-492D-968F-DA8B55D36568</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Rowe</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9827961"><gtr:id>2E6E0D16-558F-4574-B219-B5FC2781B5BB</gtr:id><gtr:title>Pathogenesis of human persistent virus infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9827961</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-04-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-04-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>299039</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Microbiology</gtr:department><gtr:description>HCMVA</gtr:description><gtr:id>7A066558-6B46-4B39-952C-C668216AFEB3</gtr:id><gtr:impact>Publications - PMID: 16271362, 16227221, 15640804</gtr:impact><gtr:outcomeId>275BD8FB4BF-1</gtr:outcomeId><gtr:partnerContribution>Reagents and intellectual input</gtr:partnerContribution><gtr:piContribution>Reagents and intellectual input</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Microbiology</gtr:department><gtr:description>HCMVB</gtr:description><gtr:id>30EA231F-450B-46D1-B064-A28A9599929D</gtr:id><gtr:impact>Publications - PMID: 16271362, 16227221, 15640804</gtr:impact><gtr:outcomeId>EEDCF1EE781-1</gtr:outcomeId><gtr:partnerContribution>Reagents and intellectual input</gtr:partnerContribution><gtr:piContribution>Reagents and intellectual input</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Biochemistry and Immunology</gtr:department><gtr:description>Cancer</gtr:description><gtr:id>64E68B0E-5B3D-4D57-ABC8-B1926E7785A9</gtr:id><gtr:impact>Grants - MRC Collaboration Grant awarded in 2005 as a continuation for this Co-operative Grant</gtr:impact><gtr:outcomeId>6FB02440D4D-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input</gtr:partnerContribution><gtr:piContribution>Intellectual input</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Biochemistry and Immunology</gtr:department><gtr:description>TNFRSF</gtr:description><gtr:id>90C31A48-9ADF-495B-AB82-8711138A35C6</gtr:id><gtr:impact>Publication - PMID: 15818692</gtr:impact><gtr:outcomeId>8966C39705B-1</gtr:outcomeId><gtr:partnerContribution>Staff, reagents and intellectual input</gtr:partnerContribution><gtr:piContribution>Reagents and intellectual input</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>188888</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Collaboration Grant</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>330829AD-1DE3-43E2-B270-B1B958C7261E</gtr:id><gtr:outcomeId>65259B93A740</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>643596</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Career Establishment Grant</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5C61C282-77A4-43F2-9559-00ECA9E61A98</gtr:id><gtr:outcomeId>4BD761E63010</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2004-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B62687D4-1991-4C1B-B58C-B7F9CAF18265</gtr:id><gtr:title>Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6bff84453c6406fcdb0850cfbe2d8d8"><gtr:id>d6bff84453c6406fcdb0850cfbe2d8d8</gtr:id><gtr:otherNames>Hsu JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5675e270bd28e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4AE0D5B-29D8-4712-B0AD-0E81CFABAA1E</gtr:id><gtr:title>Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4db494963f9a272576ab42849a536cb6"><gtr:id>4db494963f9a272576ab42849a536cb6</gtr:id><gtr:otherNames>Fielding CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a2fd63d119416.80112319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>691AF1F4-C0CC-40A8-B133-446F0AFA799B</gtr:id><gtr:title>The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0917afcd6b6c5e6031d9468f0f5ce0a0"><gtr:id>0917afcd6b6c5e6031d9468f0f5ce0a0</gtr:id><gtr:otherNames>Murrell I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a2fd2adc0f6c9.32518830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FF26EB7-360D-4CAD-A533-7258704DD609</gtr:id><gtr:title>Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab6b817c8e9b654853c81fa652b9c62"><gtr:id>4ab6b817c8e9b654853c81fa652b9c62</gtr:id><gtr:otherNames>Tomasec P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>553325B8A70</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D12A70F-BBD9-4749-8E15-E285570FFFDF</gtr:id><gtr:title>Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d2a785ff36a73dbabb9a12771c5e73e"><gtr:id>9d2a785ff36a73dbabb9a12771c5e73e</gtr:id><gtr:otherNames>Griffin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>50D6D8447EB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECFA2920-C38C-4F4C-AE27-F1C38EEA49D1</gtr:id><gtr:title>Human cytomegalovirus: taking the strain.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8a2735a3ab0c4d75ed431e7759769ce"><gtr:id>d8a2735a3ab0c4d75ed431e7759769ce</gtr:id><gtr:otherNames>Wilkinson GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>5675e2d83f6bc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64867657-5570-45F2-BCA3-4D5FF187E781</gtr:id><gtr:title>A high-efficiency system of natural killer cell cloning.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a190ea1fc342ec2d7bdfd8fbdc7115c7"><gtr:id>a190ea1fc342ec2d7bdfd8fbdc7115c7</gtr:id><gtr:otherNames>Morris RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>E802C4A686F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6062445-F142-46D3-A201-83368CD0D1B4</gtr:id><gtr:title>Genetic Stability of Bacterial Artificial Chromosome-Derived Human Cytomegalovirus during Culture In Vitro.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0917afcd6b6c5e6031d9468f0f5ce0a0"><gtr:id>0917afcd6b6c5e6031d9468f0f5ce0a0</gtr:id><gtr:otherNames>Murrell I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>585d534f10adc3.38513159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE05A35F-D419-4977-B25A-402C6067C27D</gtr:id><gtr:title>Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27f386b857f5e32f6b38b6bf2aa25fa1"><gtr:id>27f386b857f5e32f6b38b6bf2aa25fa1</gtr:id><gtr:otherNames>Siebert S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>1168FA9FC9C</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9827961</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>